We investigated the association of the OPRM1 genotype with long-term smoking cessation and change in body mass index (BMI) following a smoking cessation attempt among smokers who attempted to quit using the nicotine replacement therapy (NRT) patch or placebo in a randomized controlled trial, and were followed-up over an 8-year period following their initial cessation attempt. We also investigated possible sex differences in these relationships, given evidence for sex differences in smoking cessation and central opioid mechanisms, as well as some evidence for sex differences in response to NRT. Our results indicate that OPRM1 genotype may moderate the effect of transdermal nicotine patch compared to placebo during active treatment, with a benefit of active NRT treatment evident in the OPRM1 AA genotype group only and those carrying one or more copies of the G allele demonstrating no benefit of active NRT versus placebo patch. Our results also indicate a sex difference in change in BMI at 8-year follow-up following a smoking cessation attempt, with ex-smokers demonstrating an increase in BMI, and this increase being greater in female subjects than in male subjects. We did not observe any association of OPRM1 genotype with change in BMI, although there was a trend for genotype to influence the observed sex difference in change in BMI over time. Future studies should attempt to replicate these findings, and investigate the relationship between both short-and long-term weight gain and smoking cessation and investigate possible mechanisms that may underlie these processes. Future studies should also investigate the role of OPRM1 genotype and smoking cessation on other appetitive and reward behaviours such as alcohol consumption.
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Introduction
Cigarette smoking is the largest preventable cause of death and morbidity in the developed world 1 and, despite decades of research dedicated to improving the effectiveness of treatment, a large proportion of smokers fail to quit. 2 Although the majority of smokers show a desire to quit, in reality only a very small number of people will embark on a cessation attempt in any given year, 2 and many of those that do will relapse to smoking. 2 The wide individual variation in therapeutic response to smoking cessation pharmacotherapies has also prompted a growing interest in the study of the role of inherited factors in the efficacy of alternate pharmacotherapies.
Although the relationship between candidate genes and cigarette smoking has been widely studied, and despite a large number of association studies, a recent meta-analysis concluded that the findings remain somewhat equivocal. 5 Several possibilities exist for these discrepant results, including small sample size, potential population stratification and the use of diagnostic, categorical phenotypes rather than intermediate, continuous phenotypes (which may have the potential to afford greater statistical power). Advantages of a pharmacogenetic approach to the study of smoking cessation treatment include the use of more refined phenotypes for genetic analysis, such as the study of abstinence and relapse within participants over time. 4 To date, two pharmacogenetic trials of nicotine replacement therapy (NRT) have been conducted. On the basis of the neurobiology of reward, 6, 7 these pharmacogenetic analyses have focused on genes in the dopamine pathway, 8, 9 the serotonin pathway 10 and the opioid pathway.
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The mu-opioid receptor is expressed in multiple brain regions and mediates feelings of reward, analgesia and withdrawal. 12 It is the primary site of action for highly addictive opiates such as morphine, heroin and methadone, 13 and recent studies have shown that non-opiate drugs such as nicotine may also exert their effects by activation of opioid receptors. 6, 14 Nicotine stimulates the release of the endogenous peptide b-endorphin, 14 which has a high affinity for the mu-opioid receptor. When activated, mu receptors suppress the release of the neurotransmitter GABA, 15 although mechanisms are poorly understood. Evidence suggests that mu receptors in the ventral tegmental area (VTA) are predominantly found on GABAergic neurons, 16, 17 and when activated they decrease the levels of GABA released from GABA interneurons. 18 Dopamine projections into the nucleus accumbens have been shown to form synaptic connections with GABA neurons. 19 Thus, as GABA levels are reduced, disinhibition of VTA dopamine neurons occurs, leading to an increase in nucleus accumbens dopamine release. 20 It is this association with the mesolimbic dopamine system that has led to the investigation of the role of the mu-opioid receptor in smoking behaviour.
The Asn40Asp (A118G) polymorphism (rs1799971), found in exon I of the human mu-opioid receptor (OPRM1) gene, has been associated with functional changes in mu-opioid receptors. 21 This missense single nucleotide polymorphism (SNP) leads to the substitution of an asparagine (Asn) for an aspartate (Asp) at position 40 in the amino-acid sequence. The Asp (G) allele has been shown to bind b-endorphin three times more strongly than the Asn (A) allele, 22 although this finding has subsequently failed to replicate. 23, 24 The G allele has also been associated with reduced expression. 23 It has been reported that individuals carrying one or more copies of the G allele are more sensitive to the effects of alcohol, reporting higher subjective feelings of intoxication, stimulation, sedation and happiness compared with individuals homozygous for the A allele. 25 A recent human study indicated an association of a haplotype within OPRM1 with smoking initiation and a trend for association with nicotine dependence. 26 The involvement of this gene in nicotine dependence is also supported by linkage data. 27 Rodent studies have also shown that the OPRM1 G allele may play a role in susceptibility to addiction to alcohol, nicotine, heroin and cocaine. [28] [29] [30] [31] [32] There is considerable evidence for sex differences in smoking cessation, 33 with men demonstrating higher levels of successful cessation than women, although the evidence that men and women derive differential benefit from NRT remains equivocal. 34 It has been argued that these differences may in part be owing to sex differences in the reinforcing effects of nicotine, 35 and it is notable that there is growing evidence for sex differences in the activity of the opioid pathway. Several preclinical studies have indicated sex differences in opiate discrimination, self-administration and reward, [36] [37] [38] whereas sex has been reported to influence mu-opioid receptor binding in the human brain, 39 possibly mediated via differences in oestrogen-induced regulation. 40, 41 More recently, the OPRM1 gene has been reported to be associated with the relative reinforcing value of nicotine in women, but not in men. 42 One common fear, particularly among women, which can deter smokers from attempting to quit is the potential of weight gain following cessation. 43 The majority of adult cigarette smokers gain weight after quitting, 44 and this is associated with an increased likelihood of relapse. 45 Nicotine has long been considered an appetite suppressor, [46] [47] [48] and many studies have shown a sharp increase in eating during the first few weeks of smoking cessation. [49] [50] [51] However, food intake may not be the only operating factor, and recent studies have shown that postcessation weight gain may partially be under genetic influence. 52, 53 Genetic factors may themselves influence individual differences in the extent to which appetite is increased following smoking cessation; a recent study indicated that ex-smokers who experienced increased appetite as a nicotine withdrawal symptom during acute cessation had a higher body mass index (BMI) at 36-month follow-up than those who did not. 54 There is also evidence that there may be sex differences in change in BMI following smoking cessation. 55 In addition, there is evidence from animal studies that females may be more sensitive than males to the effects of nicotine on body weight and feeding. 47 There is also evidence from linkage data that the OPRM1 gene may be a promising candidate for obesity phenotypes such as central adiposity. 56 A recent study demonstrated that individuals with one or more copies of the G allele of the OPRM1 gene are significantly more likely to be abstinent from smoking after a course of NRT than individuals with two copies of the A allele, as well as experiencing less mood disturbance and short-term weight gain. 11 These results may be explained by the fact that smokers with the G allele gain more reward from nicotine (and, therefore, NRT), and find it easier to quit when using NRT. The difference in weight gain mirrors evidence from rodent studies linking b-endorphin and weight gain, where male knockout mice deficient in bendorphin display hyperphagia and increased body weight. 57, 58 This suggests that increased levels of b-endorphin during smoking may act as an appetite suppressor. Therefore, upon quitting using NRT, individuals carrying the G allele should experience less weight gain than those homozygous for the A allele. It is not clear from this study, however, what the effects of genotype on longer-term smoking cessation and weight gain, when ex-smokers are no longer exposed to nicotine via NRT, might be.
We therefore investigated the association of the OPRM1 genotype with long-term smoking cessation and change in BMI following a smoking cessation attempt among smokers who attempted to quit using the NRT patch or placebo in a randomized controlled trial, and were followed-up over an 8-year period following their initial cessation attempt. We also investigated possible sex differences in these relationships, given evidence for sex differences in smoking cessation and central opioid mechanisms, as well as some evidence for sex differences in response to NRT. Participants who responded at 8-year follow-up were older than non-responders (M ¼ 43 years versus M ¼ 41 years; P ¼ 0.002), more likely to be female (59 versus 53%; P ¼ 0.010) and more likely to have quit for a year in the trial (14 versus 6%; Po0.001). The OPRM1 genotype distribution of the study sample did not deviate significantly from Hardy-Weinberg equilibrium (AA ¼ 78%, AG ¼ 21%, GG ¼ 1%; P ¼ 0.75).
Results

Characteristics of participants
Analysis of smoking cessation outcomes
Logistic regression analysis (n ¼ 710) indicated a significant main effect of treatment on abstinence at 12-week follow-up (OR ¼ 2.34, 95% CI 1.55-3.57, Po0.001), with increased likelihood of abstinence in the active NRT versus placebo group, which persisted at 26-week (P ¼ 0.001) and 1-year (P ¼ 0.048) follow-up, and constituted a trend at 8-year follow-up (P ¼ 0.067).
The OPRM1 genotype Â treatment interaction was significant at 12-week follow-up (OR ¼ 0.47, 95% CI 0.23-0.99, P ¼ 0.048), indicating a significant benefit of active NRT compared to placebo in the AA group but not in the GA þ GG group at the end of treatment, but was not retained in the model for subsequent time points (i.e. after end of treatment). These data are presented graphically in Figure 1 .
The OPRM1 genotype Â sex interaction was significant or marginally significant at 12-week (OR ¼ 1.86, 95% CI 1.00-3.45, P ¼ 0.050), 26-week (P ¼ 0.051), 1-year (P ¼ 0.015) and 8-year (P ¼ 0. 005) follow-up, indicating increased likelihood of abstinence for male subjects in the AA group compared to the GA þ GG group, and the reverse pattern in female subjects. These data are presented graphically in Figure 2 .
The final logistic regression models for abstinence at 12-week, 26-week, 1-year and 8-year follow-up are presented in Table 1 . Abstinence frequencies by OPRM1 genotype group, treatment group and sex are presented in Table 2 .
Analysis of long-term change in BMI Analysis of variance of BMI (n ¼ 699) indicated a significant within-subjects main effect of time (F(1, 688) ¼ 34.24, Po0.001, Z p 2 ¼ 0.05), with increasing BMI over time, and a significant between-subjects main effect of smoking status (F(1, 688) ¼ 7.76, P ¼ 0.005, Z p 2 ¼ 0.01), with greater BMI among ex-smokers compared to smokers. The association between SES and BMI was significant (F(1, 688) ¼ 7.24, P ¼ 0.007, Z p 2 ¼ 0.01), with lower SES associated with increased BMI, whereas the association between age and BMI constituted a trend (F(1, 688) ¼ 3.17, P ¼ 0.076, Z p 2 ¼ 0.01) with greater age tending to be associated with increased BMI. In addition to the significant main effects of time and smoking status, there were significant two-way interaction AA GA+GG Figure 1 Abstinence at 12-and 26-week follow-up, by OPRM1 genotype and treatment group. Abstinence rates are presented separately for OPRM1 AA and GA þ GG genotypes, grouped by treatment (active: hatched; placebo: solid). Participants on active treatment in the AA group are more likely to be abstinent than those on placebo, whereas in the GA þ GG group no advantage of active treatment compared to placebo is observed. These effects are observed at the end of treatment (12-week follow-up), but not subsequently. To clarify the significant three-way interaction involving the within-subjects repeated measure of time, we calculated a difference score between BMI measured at baseline and at 8-year follow-up, by subtracting the former from the latter, and conducted simple effects analysis of variances stratified by smoking status. This indicated that sex was associated with BMI change among ex-smokers (F (1, 179) Mean BMI at baseline and 8-year follow-up by sex and smoking status at 8-year follow-up is presented in Table 3 .
Discussion
Our results indicate that OPRM1 genotype may moderate the effect of transdermal nicotine patch compared to placebo during active treatment, with a benefit of active NRT treatment evident in the OPRM1 AA genotype group only and those carrying one or more copies of the G allele demonstrating no benefit of active NRT versus placebo patch. This suggests that some individuals may not benefit from transdermal nicotine patch, and it is likely, given that this effect was only observed for abstinence up to the end of treatment (12-week follow-up) and not subsequently, that this represents a pharmacogenetic effect. We also observed a significant OPRM1 genotype Â sex interaction effect on abstinence, which persisted to 8-year follow-up. Among male subjects, AA genotype was associated with increased likelihood of abstinence compared to the GA þ GG group, whereas among female subjects increased likelihood of abstinence was evidence in the GA þ GG group compared to the AA group.
Our results also indicate a sex difference in change in BMI at 8-year follow-up following a smoking cessation attempt, Abstinence rates are presented separately for male and female subjects, grouped by OPRM1 genotype (AA: hatched; GA þ GG: solid). Male subjects in the AA group are more likely to be abstinent than those in the GA þ GG group, whereas the reverse is true for female subjects. with ex-smokers demonstrating an increase in BMI; this increase was greater in female subjects than in male subjects. We did not observe any association of OPRM1 genotype with change in BMI, although there was a trend for genotype to influence the observed sex difference in change in BMI over time. It is likely that our study lacked sufficient power to detect effects of genotype at 8-year follow-up. Unfortunately, we were unable to investigate weight gain over the first 1-year follow-up period for which we report abstinence outcomes. These findings are somewhat at odds with the previously reported association of OPRM1 genotype with smoking cessation and short-term weight gain following smoking cessation, where possession of one or more copies of the G allele was associated with increased likelihood of smoking cessation at end of treatment among smokers receiving NRT, as well as with reduced weight gain, 11 although we observed this pattern for abstinence in female subjects. A number of possible reasons for these discrepant results exist. The first is that the two samples (one European, one US) are drawn from populations that differ with respect to their genetic ancestry or some other characteristic that results in differing genetic associations. The similarity between the genotype frequencies observed in our European sample and the previously reported US sample argues against this interpretation, however, at least with respect to genetic ancestry. The second is that participants in the present study received either active NRT (via transdermal patch) or placebo, whereas in the previous report participants received NRT either via transdermal patch or nasal spray. The third is simply that either one or both of these sets of results reflect Type I error. This is a perennial difficulty in studies of genetic association and cannot be discounted, in particular given the modest statistical significance achieved. Clearly, further studies are required that attempt to replicate directly these findings, given the important differences in study design between this study and the previously reported study.
Lerman et al. 11 note that their observed association between the OPRM1 G allele both abstinence and reduced weight gain following smoking cessation operated during active treatment with NRT, and was no longer present at follow-up when active treatment had ceased. The authors argue that these results may be explained by increased b-endorphin occupancy at the mu-opioid receptor during NRT treatment among ex-smokers carrying the G allele. However, in this study the authors did not investigate possible sex differences, although they have subsequently reported evidence for sex differences in the association of the OPRM1 gene with the reinforcing value of nicotine. 42 Although both the previous and the present study had approximately equal numbers of male and female subjects, it is possible that the effects of OPRM1 genotype on cessation observed in the previous study may be attributable to female subjects only. Clearly we cannot test this possibility directly and future studies should further explore possible sex differences in the role of OPRM1 genotype in nicotine reward, smoking cessation and response to pharmacotherapy. The discrepancy in results also highlights the need for both treatment-treatment and treatment-placebo studies in the investigation of pharmacogenetics effects. Postcessation weight gain is known to be a predictor of relapse. 59 One possible mechanism for the observed OPRM1 genotype Â sex interaction effect on likelihood of abstinence is that these effects are mediated via postcessation weight gain. Unfortunately, BMI data were only available at baseline and 8-year follow-up in the present study, precluding a more detailed analysis of the relationship between postcessation change in BMI and abstinence over time. In the previous report, 11 measures were taken at the end of treatment (8-week follow-up) and 26-week follow-up (with no effect of genotype at the latter time point), so that our data reflect long-term change in BMI, whereas the previously reported data reflect short-term weight change whereas still on active NRT pharmacotherapy. These two outcomes may in fact reflect quite different underlying processes. Future studies should investigate long-term change in BMI and abstinence with higher temporal resolution, to clarify the relationships between sex, OPRM1 genotype, change in BMI and smoking cessation.
The observed trend for OPRM1 genotype to moderate the smoking status Â sex interaction effect on BMI change over time requires further investigation. There are also animal data suggesting that increased levels of central b-endorphin released by nicotine may suppress feeding 57, 58 and chronic nicotine administration in the rat, in doses comparable to human smoking, leads to an upregulation of mu-opioid receptors in the striatum. 60 The greater binding affinity of the G allele of the OPRM1 gene may result in proportionately greater upregulation among G allele carriers during nicotine exposure, resulting in a relatively greater change when nicotine exposure ceases and this upregulation ends. This may in turn lead to a greater relative change in seeking alternative sources of stimulation (e.g., food) among G allele carriers compared to AA homozygotes. G allele carriers demonstrate reduced expression of receptor molecules, 61 so that chronic nicotine exposure may serve to minimize differences in expression between G allele carriers and AA homozygotes. When nicotine exposure ceases this may lead to a return to baseline levels of expression, so that lower expression among G allele carriers results in greater seeking of alternative sources of stimulation (e.g., food). With equivocal data regarding the functional consequences of the Asn40Asp (A118G) polymorphism, it is difficult to identify the more likely of these two possibilities. This also suggests that smoking cessation among G allele carriers may also be associated with an increase in other appetitive and reward behaviours (e.g., alcohol consumption), although we were unable to test this possibility in our data. Future studies, however, should investigate long-term change in BMI as well as short-term change immediately following a cessation attempt.
There are several limitations to our study that should be borne in mind when considering these data. The first is that between 1-and 8-year follow-up, it is likely that smokers who relapsed to smoking following the initial clinical trial made subsequent attempts to quit. This is reflected in the curvilinear nature of the abstinence data over time. Therefore, whereas data to 12-week and possibly 26-week followup may be interpreted in the context of pharmacogenetic effects of OPRM1 genotype on response to NRT, abstinence at 1-and 8-year follow-up may better index spontaneous (possibly unaided) cessation. Unfortunately, our data do not allow us to investigate the number or nature of quit attempts in the intervening period between 1-and 8-year follow-up, and future studies should seek to address this. Second, our data only allow us to speculate regarding the possible mechanisms that may explain the observed effects of OPRM1 genotype on abstinence in male and female subjects. For example, our data did not enable the course of weight gain during this 8-year period to be analysed with high temporal resolution. Although we have outlined a number of possible explanations that are compatible with our results, our data do not allow us to test between these directly, and the question of why these results appear, at first glance, to be contrary to previous reports is a problem that we cannot resolve. Future longitudinal studies should include indices of personality traits, lipid metabolism, food reward and eating behaviour to clarify the nature of these associations. Third, we only investigated a single variant in the OPRM1 gene. According to the NCBI SNP database, there is a large amount of variation across the OPRM1 gene region, with 15 non-synonymous and four synonymous SNPs in the coding region alone. However, of these, only the Asn40Asp variant has been validated by observation of all alleles in at 21, 22 Two amino-acid changing SNPs (Asn40Asp and Ala6Val) have been reported at greater than 5% frequency, and there is good evidence that Asn40Asp exerts effects on protein expression, 21 as well as b-endorphin binding and activity. 22 More recent association studies of Asn40Asp have also included additional intronic and exonic SNPs to study the degree of linkage disequilibrium across the gene. 11, 62 Future studies should investigate multiple variants in the OPRM1 gene to afford more detailed information about variation across the gene. Fourth, despite the relatively large sample size, our study lacked power to test adequately for the association of OPRM1 genotype on change in BMI following smoking cessation and possible sex differences in this association. Future studies should investigate interactions between smoking cessation, genotype and sex in relation to BMI, although this will require larger sample sizes than are currently available.
We have demonstrated a moderating effect of OPRM1 genotype on response to active NRT compared to placebo during the active treatment phase following a smoking cessation attempt. The direction of effect that we observed, with ex-smokers carrying one or more copies of the G allele demonstrating greater increase in BMI compared to those carrying two copies of the A allele, is at odds with previous reports, although the effects we observed of OPRM1 genotype on abstinence in female subjects is consistent with these reports. We also observed a sex difference in the association of OPRM1 genotype with abstinence at all follow-up intervals. Finally, we observed a sex difference in postcessation change in BMI, with a greater increase in female ex-smokers compared to male smokers. Future studies should attempt to replicate these findings and investigate the relationship between both short-and longterm weight gain and smoking cessation, and investigate possible mechanisms that may underlie these processes. Future studies should also investigate the role of OPRM1 genotype and smoking cessation on other appetitive and reward behaviours such as alcohol consumption.
Materials and methods
Study participants
The study sample was drawn from participants in a doubleblind randomized placebo-controlled trial of the nicotine transdermal patch (the PATCH study) conducted in 1991-1992, 63 which recruited 1686 heavy smokers (X15 cigarettes per day). Participants were given sufficient patches for 12 weeks. Abstinence from smoking at 1-week follow-up was confirmed by expired carbon monoxide concentration (p10 p.p.m.), and at 12-week, 26-week and 1-year followup by salivary cotinine concentration (p20 ng/ml; 89% of cases) or expired carbon monoxide concentration (p10 p.p.m.). Information was collected initially by postal questionnaire and confirmed at a subsequent face-to-face interview with a trained nurse. Data collected at baseline included age in years, sex, BMI in kg/m 2 , SES, self-reported ancestry and self-reported smoking habits, including a measure of nicotine dependence using the Horn-Russell scale.
In 1999-2000, we contacted n ¼ 1532 of the n ¼ 1625 living participants to retrospectively investigate genetic determinants of smoking cessation success (the PATCH 2 study), 9, 64 of whom a total of n ¼ 767 responded (50% of those contacted). Mean time from trial to follow-up was 8 years. Reported abstinence at 8-year follow-up was confirmed by plasma nicotine concentration (p20 ng/ml). Throughout, non-responders were assumed to be smoking. Information was collected by postal questionnaire and a blood sample collected by the participant's GP. Data collected at 8-year follow-up included age in years, sex, BMI in kg/m 2 , SES, self-reported ancestry and self-reported smoking habits.
In the present study, participants were excluded if participants reported being of non-European ancestry (n ¼ 11), if DNA was not available (n ¼ 12) or if OPRM1 genotype data (n ¼ 20), SES data (n ¼ 17) or nicotine dependence data (n ¼ 1) were missing. For the analysis of smoking cessation outcomes, participants not available at follow-up were considered as continuing smokers (i.e. intent-to-treat analysis), and abstinence was defined as biochemically validated point-prevalence 7-day abstinence. For the analysis of long-term change in BMI, participants were excluded if data enabling the calculation of BMI data were missing at either baseline (n ¼ 5) or 8-year follow-up (n ¼ 7).
The final study sample on which complete data were available, therefore, consisted of an ethnically homogeneous group of male and female heavy smokers before and after a smoking cessation attempt, during which they were randomized to receive either active NRT or placebo. The sample for analysis of smoking cessation outcomes (n ¼ 710) represented 92% of those who responded at followup and 46% of those initially contacted at follow-up. The sample for analysis of long-term change in BMI (n ¼ 699) represented 91% of those who responded at follow-up and 45% of those initially contacted at follow-up. The study was approved by the local research ethics committee (IRB).
Genotyping
Plasma and buffy coat lymphocytes from the PATCH 2 study were stored at À801C until required for analysis. DNA was extracted using a standard 'salting-out' technique. 65 For the genotyping of the OPRM1 A118G polymorphism, PCR was carried out using an allele-specific, two-tube primer method. The reaction mixture contained 0.5 mM of each OPRM1 and control primer, approximately 150 ng of DNA, 200 mM dNTPs, 2 mM MgCl 2 and 0.5 U of Taq polymerase in a final volume of 25 ml. After an initial denaturation step for 10 min at 951C, thermocycling consisted of 30 cycles of 951C for 20 s, 681C for 45 s and 721C for 30 s. A final extension phase of 721C was followed by cooling of samples to 41C. PCR products were separated on a 1% agarose gel at 200 V for OPRM1 genotype and smoking cessation MR Munafò et al 30 min and visualized using ethidium bromide. For samples to be valid, a 750 bp control product had to be formed in both allele-specific reactions. A homozygote was indicated by the presence of a 561 bp product in one of the reactions and a heterozygote was represented by a 561 bp product in both of the reactions.
Statistical analysis
For the analysis of smoking cessation outcomes, separate models of biochemically validated abstinence at 12-week (end of treatment), 26-week, 1-year and 8-year follow-up were generated within a logistic regression framework, using the backwards conditional method, with term removal conditional on P40.10. The full model included age, sex, SES and nicotine dependence at baseline, treatment group (transdermal patch, placebo), OPRM1 genotype (AA, GA þ GG), and interaction terms for treatment Â sex, treatment Â genotype, sex Â genotype and treatment Â sex Â genotype.
For the analysis of long-term change in BMI, a fullfactorial mixed model repeated measures 2 Â 2 Â 2 Â 2 analysis of variance, with smoking status at 8-year followup (current smoker, ex-smoker), sex (male, female) and OPRM1 genotype (AA, GA þ GG) as between-subjects factors, and time (baseline, 8-year follow-up) as a within-subjects repeated measure factor was performed, with BMI at baseline and 8-year follow-up as the dependent variables. Age, SES and nicotine dependence score at baseline were included as covariates. Greenhouse-Geisser corrections were employed where appropriate.
OPRM1 GA and GG genotypes were combined owing to the small number of participants with GG genotype (n ¼ 11). All analyses were performed using the Statistical Package for the Social Sciences (v. 12.0).
